REPLY

Natürliche Intelligenz.

Home Fachkreise - Unsere Produkte Cardiac Rhythm Management HERZSCHRITTMACHER REPLY

REPLY

Eine Schrittmacherfamilie inspiriert durch die Natur. Natürliche Intelligenz.

Das kleinste Zweikammergerät der Welt ohne Kompromisse bei der Laufzeit.1–3

Reply DR beinhaltet SafeRTM, den einzigen AV-Management-Algorithmus, dessen Sicherheit und Effektivität für alle Patienten mit Bradyarrhythmie belegt ist.1, 4

12 Jahre Laufzeit bei nur 8 cm3.


REPLY REPLY 200 DR Micro Port 2018 1

SafeRTM

  • Erweitertes AV-Block-Management für besseren Schutz5, 7–13
  • Reduziert RV Stimulation bei SND- und AVB-Patienten5
  • Managt ALLE Arten von AV-Blockierungen in Ruhe und unter Belastung2, 5
  • Verlängert die Gerätelaufzeit um 2 Jahre12, 13
  • Einzigartige AV-Blockdiagnostik Unique AV block diagnosis
REPLY Kora3 1

Dual sensorTM

  • Anpassung an metabolische Bedürfnisse. Sichere Belastung
  • Designt für die physiologische Anpassung des Herzrhythmus durch Kombination von Akzelerometer und Atemminutenvolumensensor


REFERENZEN

  1. Sorin implant manuals (Reply – 0979-0980-O981-O982) available at www.microportmanuals.com
  2. Competition comparison across transvenous pacing systems made as of September 2020, refer to manufacturers manuals available online
  3. Reply with typical conditions using SafeR: 50% A pacing, 5% V pacing, 60 bpm, 2.5V, 0.35ms, 750 ohms, EGM & Diagnostics ON, Sensors ON.
  4. Stockburger M, et al. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in general population (ANSWER study). Euro Heart J. 2015;36:151–57.
  5. Andersen HR, et al. Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997; 350:1210-16.
  6. Skanes AC, et al. Progression to chronic atrial fibrillation after pacing: The Canadian Trial Of Physiologic Pacing (CTOPP). J Am Coll Cardiol. 2001; 38:167–72.
  7. Nielsen J, et al. A randomized comparison of atrial and dual chamber pacing in 177 consecutive patients with sick sinus syndrome. J Am Coll Cardiol. 2003; 42:614–23.
  8. Sweeney M, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107: 2932–37.
  9. Wilkoff BL, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID trial). JAMA. 2002;288:3115–23.
  10. Stockburger M, et al. Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity-a substudy of the ANSWER trial. Europace 2016;18:739–46.
  11. Benkemoun H, et al. Optimizing pacemaker longevity with pacing mode and settings programming: results from a pacemaker multicenter registry. Pacing Clin Electrophysiol 2012;35:403–08.

By following this link, you will leave this site. To return, use the browser tabs or browse the browser history.

Continue